4-Year Open-Label Extension Phase of the Parallel-Group Study of E2007 in Patients With Refractory Partial Seizures
Completed
Eisai Inc.
Phase 2
2006-10-01
The purpose of this study is to determine the safety of perampanel given as adjunctive,
long-term treatment in patients with refractory partial onset seizures.
Evaluation of the Long-term Safety, Tolerability, and Efficacy of Perampanel (E2007) as an Adjunctive Therapy in Levodopa Treated Parkinson's Disease Subjects With Motor Fluctuations
Terminated
Eisai Limited
Phase 3
2007-07-01
This is a multicentre, open-label extension study to evaluate the long-term safety,
tolerability, and efficacy of Perampanel (E2007) as an adjunctive therapy in levodopa treated
PD subjects with motor fluctuations. All subjects who have completed E2007-E044-213 or
E2007-G000-309 will be candidates for entering this extension trial, provided that they meet
the inclusion/exclusion criteria and have completed the core study, up to and including the
final efficacy visit.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
